MCAM for Opioid Use Disorder

This trial tests a new drug called MCAM for individuals with opioid use disorder. The main goal is to determine if MCAM is safe and if it causes any side effects when taken orally. Researchers aim to understand how the drug moves in the blood, how quickly it starts working, and how long its effects last. Participants will receive either the drug or a placebo (a harmless pill with no active medicine) to compare results. Individuals who have used opioids for non-medical reasons at least 10 times in the past year and at least once in the past 12 weeks may be suitable for this trial. As an Early Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

Yes, participants must stop taking any prescription or over-the-counter medications, including vitamins and supplements, at least 14 days before the screening or 5 half-lives before the study.

Research shows that MCAM appears safe. In earlier studies, MCAM demonstrated potential long-lasting benefits without causing harm. It works by blocking certain brain areas affected by opioids, helping to reduce opioid use and prevent overdoses.

Importantly, studies found that MCAM does not cause memory problems, a common concern with many drugs. Animal tests showed it successfully reduced opioid use without major side effects. However, limited information exists about its effects on humans, as testing in people has just begun. More research is needed to fully understand its safety for humans.

Unlike the standard treatments for opioid use disorder, which often include medications like methadone, buprenorphine, and naltrexone, MCAM offers a unique approach. MCAM works by targeting specific receptors in the brain, potentially blocking the effects of opioids more effectively. Additionally, it is administered orally, which could make it easier for patients to use consistently. Researchers are excited because MCAM might provide a new mechanism of action that could help patients who don't respond well to existing therapies.

This trial will evaluate MCAM for opioid use disorder. Studies have shown that MCAM can help reduce opioid use and prevent overdoses. One study found that MCAM lowered fentanyl use and stopped overdoses more effectively with higher doses, indicating that increased doses improved its effectiveness. Another important finding is that MCAM remains effective even at low blood levels due to its strong attachment to opioid receptors. Research suggests that MCAM can serve as a long-term solution for opioid use disorder by blocking the effects of opioids. Overall, MCAM shows promise in treating opioid addiction and reducing overdose deaths. Participants in this trial will be assigned to different treatment arms, including varying doses of MCAM and placebo, to further assess its effectiveness.¹⁵⁶⁷⁸